Episode Details
Back to Episodes187 - Trump Legalizes Medical Marijuana, China Beat Nvidia Without Chips, Gene Therapy Restores Hearing
Description
Vic and Marcus recap insights from the Health Evolution Summit, focusing on high-value networking versus weak conference content, then break down major economic and policy developments including Kevin Warsh’s expected appointment as Fed Chair, the end of the investigation into Jerome Powell, and shifts in Fed governance. They cover venture activity across AI healthcare, biotech resurgence, and crowded revenue cycle startups, alongside new accelerators backed by Anne Wojcicki. Policy wins include FDA gene therapy breakthroughs, marijuana reclassification, and faster CMS coverage pathways. The episode dives into payer performance with improved MLR trends, ongoing health system struggles, and biotech deal momentum led by Eli Lilly. They explore AI’s growing role in healthcare, including dementia care and OpenAI launching clinical tools, while also unpacking infrastructure pressures from data center demand, chip innovation, and inference growth. The episode closes with geopolitical tensions in AI, highlighting Nvidia vs China debates, the rise of DeepSeek, and rapid advancements in robotics performance.
Links
Story 1: Kevin Warsh - Fed
5:12 - Warsh Pledges Independence at Fed Hearing WSJ
6:11 - DOJ drops investigation into Fed’s Powell Roll Call
Story 2: VC
11:59 - Courier Health scores $50M to scale CRM technology Mobi Heath
13:19 - Esther and Anne Wojcicki back new healthcare accelerator, fund TechCrunch
Story 3: 1st Gene Therapy
14:54 - FDA Approves First-Ever Gene Therapy to Restore Hearing WSJ
Story 4: Marijuana reclassified
16:51 - Trump Administration Reclassifies Marijuana as Less Dangerous Drug WSJ
Story 5: RAPID
18:44 - CMS and FDA announce RAPID Medicare coverage for breakthrough medical devices Healthcae Finance
Story 6: Payor Financial Reports
20:43 - UnitedHealth Shows Signs of Turnaround With Strong Quarterly Results WSJ
21:58 - Molina controls costs in Q1 but future Medicaid spending in doubt Healthcar